Seqanswers Leaderboard Ad

Collapse

Announcement

Collapse
No announcement yet.
X
 
  • Filter
  • Time
  • Show
Clear All
new posts

  • U.S. Supreme Court : "Can't Patent Genes"

    The Supreme Court ruled Thursday that companies cannot patent parts of naturally-occurring human genes, a decision with the potential to profoundly affect the emerging and lucrative medical and biotechnology ...


    WASHINGTON (AP) -- The Supreme Court ruled Thursday that companies cannot patent parts of naturally-occurring human genes, a decision with the potential to profoundly affect the emerging and lucrative medical and biotechnology industries.
    The high court's unanimous judgment reverses three decades of patent awards by government officials.

  • #2
    It seems to me that for all practical purposes, the Myriad gene patents are upheld (wall street seems to agree with that too). Even though isolated DNA is not eligible for patents like it was before, the cDNA product that is created in the lab is still eligible for patents. So our genes are patent-free but we are blind to read them?

    Justin

    Comment


    • #3
      Agreed.


      The Supreme Court this morning ruled that human DNA cannot be patented. On the surface it appears to be a blow to Myriad Genetics, which was holding patents on two isolated genes, known as BRCA1 and BRCA2, and was at the center of the case. The genes can help indicate whether a woman has a heightened risk of developing breast or ovarian cancer, and it was the company’s test based upon them that convinced the actress Angelina Jolie to recently undergo a double-mastectomy.

      But the ability to patent another type of DNA, known as cDNA, was upheld, and it’s this partial verdict that has Myriad shares up. The court said DNA molecules synthesized in a laboratory were eligible for patent protection.


      Dang. Myriad won. You can't patent genes but you can patent the cDNA of the genes. So any practical assay of of BRCA1 and BRCA2 are owned by Myriad? You need cDNA to assay it , right?

      Comment


      • #4
        Only if you are going to try to make money off of it. Then you just have to negotiate licensing. It doesn't interfere with non-profit research. At least that's what I've learned from the patents office where I work.
        /* Shawn Driscoll, Gene Expression Laboratory, Pfaff
        Salk Institute for Biological Studies, La Jolla, CA, USA */

        Comment


        • #5
          Don't all human mrna tissue samples get converted to cDNA for sequencing? I guess the question is how novel is patenting a cDNA? It seems like just about every MicroArray or RNA-seq experiment could potentially generate BRCA1 inadvertently, I am pretty sure they were producing cDNA of BRCA1 before they applied for a patent. Unless the scope is narrowed to producing a BRCA1 cDNA for a specific purpose maybe gene replacement therapy for instance, then it doesn't make much sense.

          Comment

          Latest Articles

          Collapse

          • seqadmin
            Essential Discoveries and Tools in Epitranscriptomics
            by seqadmin




            The field of epigenetics has traditionally concentrated more on DNA and how changes like methylation and phosphorylation of histones impact gene expression and regulation. However, our increased understanding of RNA modifications and their importance in cellular processes has led to a rise in epitranscriptomics research. “Epitranscriptomics brings together the concepts of epigenetics and gene expression,” explained Adrien Leger, PhD, Principal Research Scientist...
            04-22-2024, 07:01 AM
          • seqadmin
            Current Approaches to Protein Sequencing
            by seqadmin


            Proteins are often described as the workhorses of the cell, and identifying their sequences is key to understanding their role in biological processes and disease. Currently, the most common technique used to determine protein sequences is mass spectrometry. While still a valuable tool, mass spectrometry faces several limitations and requires a highly experienced scientist familiar with the equipment to operate it. Additionally, other proteomic methods, like affinity assays, are constrained...
            04-04-2024, 04:25 PM

          ad_right_rmr

          Collapse

          News

          Collapse

          Topics Statistics Last Post
          Started by seqadmin, Yesterday, 08:47 AM
          0 responses
          14 views
          0 likes
          Last Post seqadmin  
          Started by seqadmin, 04-11-2024, 12:08 PM
          0 responses
          60 views
          0 likes
          Last Post seqadmin  
          Started by seqadmin, 04-10-2024, 10:19 PM
          0 responses
          60 views
          0 likes
          Last Post seqadmin  
          Started by seqadmin, 04-10-2024, 09:21 AM
          0 responses
          54 views
          0 likes
          Last Post seqadmin  
          Working...
          X